Aribio, a bio-healthcare company, announced on April 23 that its electronic drug for dementia, currently under development, has recently completed patient recruitment for clinical trials and has officially entered the trial phase.
The company explained that it is attracting attention as an innovative leader in next-generation dementia treatment technologies by simultaneously developing AR1001, an oral Alzheimer's treatment currently in Phase 3 clinical trials across 13 countries worldwide, and its electronic drug.
Aribio's electronic drug for dementia utilizes its patented "brain acoustic vibration" technology. This technology delivers specific low-frequency acoustic vibrations through the skull to non-invasively stimulate neural pathways in the brain. Instead of delivering medication, it uses electronic stimulation to activate neural networks and slow the progression of Alzheimer's disease, positioning it as a next-generation cognitive impairment treatment device. Additionally, as a non-pharmaceutical solution targeting the rapidly increasing demand for dementia treatment due to population aging, expectations for its commercialization are high.
The clinical trial for the dementia electronic drug is being conducted in collaboration with the research team led by Professor Kim Sangyun of the Department of Neurology at Bundang Seoul National University Hospital. The study targets 30 patients with early-stage Alzheimer's disease and employs a multi-center, randomized, double-blind, parallel design. Following the safety and efficacy evaluation results expected at the end of October, an additional six months of extended observation will be conducted.
This clinical trial was selected as a support project for "New Medical Device Approval Helper" by the Ministry of Food and Drug Safety, receiving administrative and technical consulting necessary for device commercialization. The company stated that, based on its selection for government research projects and collaboration with multiple medical institutions, it has secured technological credibility, which is expected to have a positive impact on future business performance and corporate valuation.
An Aribio representative stated, "We plan to expand the indications for our brain stimulation electronic drug technology to various neurodegenerative diseases such as Parkinson's disease and vascular dementia, and we are also planning overseas clinical trials in the United States and Europe. With a multi-pronged strategy involving both the oral treatment AR1001 and the electronic drug, we are aiming to conquer dementia and enter the global market."
Meanwhile, Aribio is pursuing a merger with Solux. The scheduled merger date for the two companies is August 1.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
